Joint Formulary & PAD

Ocrelizumab - Multiple sclerosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Infusion
Associated Icons :
BNF SPC
NHSE
Restrictions / Comments :
Important

ASPH are the only Surrey Heartlands Trust commissioned to provide this.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Ocrelizumab
Indication :
Multiple sclerosis
Group Name :
Keywords :
RRMS, MS, active, relapsing
Brand Names Include :
Ocrevus
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Ocrelizumab is used to treat.

  • No records returned.

Committee Recommendations (1)

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care. Treatment should remain with the specialist (RED) hospital only drug.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.